3188848
Last Update Posted: 2019-01-02
Recruiting status is unknown
All Genders accepted | 18 Years-45 Years |
63 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Dose Escalating Study of BPI-3016 in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, dose finding study evaluating the safety, pharmacokinetics and pharmacodynamics of subcutaneously injected BPI-3016 in Chinese healthy subjects.
BPI-3016 is a novel analogue of glucagon-like peptide-1 (GLP-1) that developed for the treatment of type 2 diabetes mellitus. This is a randomized, double-blind, placebo-controlled, dose finding study evaluating the safety, pharmacokinetics and pharmacodynamics of subcutaneously injected BPI-3016 in Chinese healthy subjects.
Eligibility
Relevant conditions:
Healthy Subject
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov